WASHINGTON, Dec. 21 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration issued a notice determining that Zantac injection was not withdrawn from sale for reasons of safety or effectiveness, provided manufacturing meets specific impurity limits. This ruling clears a path for pharmaceutical companies to seek approval for generic versions of the drug.

Zantac injection, used to treat ulcers and hypersecretory conditions in hospitalized patients, was . . .

Click here for more information about our products